EUVIMEDEUVIMED entdecken
Crossref

Oveporexton: First Approval

Michael B Brown

Drugs · 17.11.2026

DOI: 10.1007/s40265-026-02401-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs, online erschienen am 17.11.2026. Verfasst von Michael B Brown. Beteiligte Einrichtung: Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com. Die Arbeit nennt 19 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oveporexton (ORZEYFUL^TM) is an oral selective orexin receptor 2 agonist developed by Takeda Pharmaceuticals Inc. for the treatment of narcolepsy type 1 (NT1). Oveporexton received its first approval in China on 22 July 2026 for the treatment of adolescents aged ≥ 16 years and adults with NT1. Subsequently, oveporexton was approved on 5 August 2026 in the USA and on 24 August 2026 in Japan for adults with NT1. Targeting the underlying orexin deficiency in NT1, oveporexton is the first and only agent approved for the treatment of NT1 addressing the full range of symptoms which define the condition. Additional global filings and phase III clinical trials are ongoing. This article summarizes the milestones in the development of oveporexton leading to this first approval for NT1.

Autor:innen und Institutionen

  • Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Brown, M. B. (2026). Oveporexton: First Approval. Drugs. https://doi.org/10.1007/s40265-026-02401-2

Vancouver

Brown MB. Oveporexton: First Approval. Drugs. 2026. doi:10.1007/s40265-026-02401-2

BibTeX
@article{Brown2026,
  author = {Brown, Michael B},
  title = {Oveporexton: First Approval},
  journal = {Drugs},
  year = {2026},
  doi = {10.1007/s40265-026-02401-2}
}
Kostenlos starten →